Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prevention and treatment of synucleinopathic disease

a technology of synucleinopathy and disease, applied in the direction of antibody medical ingredients, carrier-bound antigen/hapten ingredients, immunological disorders, etc., can solve the problems of patient risk factor for disease and asymptomatic, and achieve the effect of improving patient motor characteristics and preventing deterioration of patient motor characteristics

Inactive Publication Date: 2011-06-09
JANSSEN ALZHEIMER IMMUNOTHERAPY +1
View PDF75 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes methods and compositions for preventing or treating diseases characterized by the buildup of proteins in the brain, such as Parkinson's disease and Alzheimer's disease. The methods involve inducing an immunogenic response against the proteins, either by administering an immunogen or an antibody to the patient. The immunogen can be administered through various routes, such as injection or orally. The method can also involve administering a second agent that induces an immunogenic response against a different component of the disease. The patent also describes pharmaceutical compositions containing the immunogenic response inducing agent. Overall, the patent provides new ways to develop treatments for these neurological diseases.

Problems solved by technology

In some methods the patient has a risk factor for the disease and is asymptomatic.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prevention and treatment of synucleinopathic disease
  • Prevention and treatment of synucleinopathic disease
  • Prevention and treatment of synucleinopathic disease

Examples

Experimental program
Comparison scheme
Effect test

examples

I. Immunization of Human Alpha-Synuclein Transgenic Mice with Human Alpha-Synuclein Results in the Production of High Titer Anti-Alpha-Synuclein Antibodies that Cross the Blood-Brain Barrier

[0190]Full-length recombinant human alpha-SN was resuspended at a concentration of 1 mg / ml in 1× phosphate buffered saline (PBS). For each injection, 50 μl of alpha-SN was used; giving a final concentration of 50 μg per injection to which 150 μl of 1×PBS was added. Complete Freund's adjuvant (CFA) was then added 1:1 to either alpha-SN or PBS alone (control), vortexed and sonicated to completely resuspend the emulsion. For the initial injections, eight D line human alpha-SN transgenic (tg) single transgenic 4-7 months old mice (Masliah, et al. Science 287:1265-1269 (2000) received injections of human alpha-SN in CFA and, as control, four D line human alpha-SN tg mice received injections of PBS in CFA. Mice received a total of 6 injections. Three injections were performed at two weeks intervals and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
body weightaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit under 35 U.S.C. §119(e) of U.S. Application No. 60 / 423,012, filed Nov. 1, 2002, which is incorporated by reference herein for all purposes.BACKGROUND OF THE INVENTION[0002]Alpha-synuclein (alphaSN) brain pathology is a conspicuous feature of several neurodegenerative diseases, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), the Lewy body variant of Alzheimer's disease (LBVAD), multiple systems atrophy (MSA), and neurodegeneration with brain iron accumulation type-1 (NBIA-1). Common to all of these diseases, termed synucleinopathies, are proteinaceous insoluble inclusions in the neurons and the glia which are composed primarily of alphaSN.[0003]Lewy bodies and Lewy neurites are intraneuronal inclusions which are composed primarily of alphaSN. Lewy bodies and Lewy neurites are the neuropathological hallmarks Parkinson's disease (PD). PD and other synucleinopathic diseases have been co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K39/00A61K39/385A61P37/04A61P25/00A61BA61B1/00A61K38/17A61K45/06A61K47/48A61K51/10A61P25/16A61P25/28C12Q1/00C12Q1/02G01N33/53
CPCA61K38/1709A61K39/0007A61K2039/55566A61K51/1078A61K45/06A61P25/00A61P25/16A61P25/28A61P37/04A61P43/00
Inventor SCHENK, DALE B.MASLIAH, ELIEZER
Owner JANSSEN ALZHEIMER IMMUNOTHERAPY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com